|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
N/A |
Shares
Out: |
61,150,000 |
Market
Cap: |
6.68(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$113.49 - $145.93 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
12,000 |
12,000 |
12,000 |
Total Buy Value |
$0 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
1 |
Total Shares Sold |
5,000 |
8,704 |
24,601 |
181,935 |
Total Sell Value |
$548,250 |
$986,699 |
$3,178,219 |
$26,303,629 |
Total People Sold |
1 |
2 |
12 |
19 |
Total Sell Transactions |
1 |
3 |
19 |
67 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Young Matthew P. |
EVP & CFO |
|
2019-02-27 |
4 |
AS |
$137.91 |
$121,912 |
D/D |
(884) |
27,967 |
|
- |
|
Hooper Suzanne Sawochka |
EVP & General Counsel |
|
2019-02-27 |
4 |
AS |
$140.00 |
$933,240 |
D/D |
(6,666) |
39,738 |
|
- |
|
Hooper Suzanne Sawochka |
EVP & General Counsel |
|
2019-02-27 |
4 |
OE |
$46.83 |
$312,169 |
D/D |
6,666 |
46,404 |
|
- |
|
Miller Michael Patrick |
EVP, US Commercial |
|
2019-02-26 |
4 |
D |
$127.76 |
$52,893 |
D/D |
(414) |
24,103 |
|
- |
|
Wilson Karen J |
SVP, Finance & PAO |
|
2019-02-26 |
4 |
D |
$127.76 |
$29,385 |
D/D |
(230) |
15,463 |
|
- |
|
Mcgill Iain |
SVP, Europe & Rest of World |
|
2019-02-26 |
4 |
D |
$127.76 |
$50,337 |
D/D |
(394) |
21,105 |
|
- |
|
Young Matthew P. |
EVP & CFO |
|
2019-02-26 |
4 |
D |
$127.76 |
$132,104 |
D/D |
(1,034) |
28,851 |
|
- |
|
Young Matthew P. |
EVP & CFO |
|
2019-02-26 |
4 |
AS |
$125.93 |
$129,960 |
D/D |
(1,032) |
29,885 |
|
- |
|
Hooper Suzanne Sawochka |
EVP & General Counsel |
|
2019-02-26 |
4 |
D |
$127.76 |
$84,705 |
D/D |
(663) |
39,738 |
|
- |
|
Cozadd Bruce C |
Chairman & CEO |
|
2019-02-26 |
4 |
D |
$127.76 |
$436,939 |
D/D |
(3,420) |
271,589 |
|
- |
|
Miller Michael Patrick |
EVP, US Commercial |
|
2019-02-25 |
4 |
D |
$126.25 |
$66,660 |
D/D |
(528) |
24,517 |
|
- |
|
Wilson Karen J |
SVP, Finance & PAO |
|
2019-02-25 |
4 |
D |
$126.25 |
$39,138 |
D/D |
(310) |
15,693 |
|
- |
|
Mcgill Iain |
SVP, Europe & Rest of World |
|
2019-02-25 |
4 |
D |
$126.25 |
$69,311 |
D/D |
(549) |
21,499 |
|
- |
|
Young Matthew P. |
EVP & CFO |
|
2019-02-25 |
4 |
D |
$126.25 |
$153,773 |
D/D |
(1,218) |
30,917 |
|
- |
|
Hooper Suzanne Sawochka |
EVP & General Counsel |
|
2019-02-25 |
4 |
D |
$126.25 |
$98,854 |
D/D |
(783) |
40,401 |
|
- |
|
Cozadd Bruce C |
Chairman & CEO |
|
2019-02-25 |
4 |
D |
$126.25 |
$338,224 |
D/D |
(2,679) |
275,009 |
|
- |
|
Swisher Daniel N Jr |
President and COO |
|
2019-01-03 |
4 |
D |
$126.01 |
$202,120 |
D/D |
(1,604) |
16,512 |
|
- |
|
Hooper Suzanne Sawochka |
EVP & General Counsel |
|
2018-12-14 |
4 |
AS |
$140.21 |
$467,460 |
D/D |
(3,334) |
41,184 |
|
- |
|
Hooper Suzanne Sawochka |
EVP & General Counsel |
|
2018-12-14 |
4 |
OE |
$46.83 |
$154,305 |
D/D |
3,295 |
44,518 |
|
- |
|
Cozadd Bruce C |
Chairman & CEO |
|
2018-12-03 |
4 |
AS |
$151.78 |
$151,780 |
D/D |
(1,000) |
277,688 |
|
- |
|
Young Matthew P. |
EVP & CFO |
|
2018-11-23 |
4 |
AS |
$150.00 |
$105,000 |
D/D |
(700) |
32,068 |
|
- |
|
Mulligan Seamus |
Director |
|
2018-11-15 |
4 |
B |
$141.86 |
$7,228,001 |
D/D |
50,000 |
1,100,868 |
2.39 |
- |
|
Miller Michael Patrick |
EVP, US Commercial |
|
2018-11-13 |
4 |
AS |
$149.27 |
$29,854 |
D/D |
(200) |
24,972 |
|
- |
|
Cozadd Bruce C |
Chairman & CEO |
|
2018-11-01 |
4 |
AS |
$159.45 |
$207,290 |
D/D |
(1,300) |
278,615 |
|
- |
|
Young Matthew P. |
EVP & CFO |
|
2018-10-15 |
4 |
AS |
$158.08 |
$110,658 |
D/D |
(700) |
32,768 |
|
- |
|
881 Records found
|
|
Page 17 of 36 |
|
|